Allarity Therapeutics Inc. has announced new and updated clinical data from its ongoing Phase 2 trial evaluating stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, in patients with advanced ovarian cancer. The results, which were presented at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer held September 19-21, 2025, in Denver, Colorado, show that median overall survival among platinum-resistant and refractory ovarian cancer patients receiving stenoparib/2X-121 twice daily has now surpassed 25 months. Clinical benefit was observed in patients with both BRCA wild-type and BRCA-mutated genetics. The company noted that two patients remain on therapy after more than 24 months, including one with primary platinum-refractory disease who remains alive more than two years after enrollment. The data are available via the scientific publications section of Allarity Therapeutics' website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-090872), on September 24, 2025, and is solely responsible for the information contained therein.
Comments